Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma.
作者信息
Sharon Cimarron E, Tortorello Gabriella N, Ma Kevin, Sinnamon Andrew J, Mitchell Tara C, Karakousis Giorgos C, Miura John T
机构信息
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Ann Surg Oncol. 2023 Sep;30(9):5329-5332. doi: 10.1245/s10434-023-13736-5. Epub 2023 Jun 19.
Abstract
摘要
相似文献
1
Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma.辅助免疫疗法对当代 III 期黑色素瘤患者总生存期的影响
Ann Surg Oncol. 2023 Sep;30(9):5329-5332. doi: 10.1245/s10434-023-13736-5. Epub 2023 Jun 19.
2
Adjuvant immunotherapy. Treatment of high risk patients with malignant melanoma.辅助免疫疗法。恶性黑色素瘤高危患者的治疗。
J Kans Med Soc. 1978 Mar;79(3):107-10.
3
Phase III adjuvant studies in operable malignant melanoma (review).可手术恶性黑色素瘤的III期辅助性研究（综述）
Anticancer Res. 1987 Jul-Aug;7(4B):701-5.
4
5
[Immune modulators in the treatment of malignant melanoma].[免疫调节剂在恶性黑色素瘤治疗中的应用]
Fortschr Med. 1989 Feb 10;107(4):41-2, 45.
6
Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine.用卡介苗对恶性黑色素瘤进行免疫治疗后发生的原发性接种性肺结核。
J Am Acad Dermatol. 1996 Nov;35(5 Pt 1):783-5.
7
Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.卡介苗免疫疗法治疗恶性黑色素瘤后出现的远处皮肤肉芽肿：直接感染病例
Clin Infect Dis. 1999 Dec;29(6):1569-70. doi: 10.1086/313543.
8
Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?以安慰剂或无治疗作为对照臂的黑色素瘤辅助治疗：在伦理上是否正确？
Melanoma Res. 1999 Oct;9(5):528-9.
9
Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.用牛痘黑色素瘤溶瘤产物进行主动特异性辅助免疫治疗。
Ann Plast Surg. 1992 Jan;28(1):108-9. doi: 10.1097/00000637-199201000-00027.
10
Adjuvant treatment of cancer. III. Malignant melanoma.癌症的辅助治疗。III. 恶性黑色素瘤。
Conn Med. 1978 Apr;42(4):220-2.
引用本文的文献
1
A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma.一项针对前哨淋巴结活检的综合31基因表达谱检测（i31-GEP用于SLNB）的前瞻性多中心分析表明，皮肤黑色素瘤患者中不必要的前哨淋巴结活检数量有所减少。
World J Surg Oncol. 2025 Jan 3;23(1):5. doi: 10.1186/s12957-024-03640-x.
2
Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort Study.可手术临床III期黑色素瘤免疫治疗的顺序与结局：一项全国队列研究
J Surg Oncol. 2025 Mar;131(3):365-370. doi: 10.1002/jso.27933. Epub 2024 Oct 3.
3
ASO Author Reflections: Evaluating the Relationship Between Patient Comorbidities and Stage at Diagnosis for Breast and Colon Cancers.美国骨科学会作者反思：评估乳腺癌和结肠癌患者合并症与诊断分期之间的关系。
Ann Surg Oncol. 2023 Aug;30(8):4627-4628. doi: 10.1245/s10434-023-13606-0. Epub 2023 May 9.
本文引用的文献
1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.辅助帕博利珠单抗对比安慰剂用于切除的 III 期黑色素瘤（EORTC 1325-MG/KEYNOTE-054）：来自一项双盲、随机、对照、III 期试验的无远处转移生存结果。
Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12.
2
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络（NCCN）指南及证据水平对美国食品药品监督管理局（FDA）批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.
3
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.纳武利尤单抗辅助治疗与伊匹单抗用于切除的 III 期或 IV 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
4
The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.国家癌症数据库：一项改善美国癌症护理的有力举措。
Ann Surg Oncol. 2008 Mar;15(3):683-90. doi: 10.1245/s10434-007-9747-3. Epub 2008 Jan 9.
Zotero 插件